• Tuberculosis and Respiratory Diseases
• /
• v.48 no.5
• /
• pp.740-747
• /
• 2000

Background : To compare the efficacies and side effects of etoposide, cisplatin/cyclophosphamide, adriamycin, vincristine(VPP/CAV) with those of carboplatin etoposide(CE) in extensive stage small cell lung cancer patients. Method : Patients with extensive stage small lung cancer who has measurable disease were eligible. VPP/CAV group(n=22) was treated with cisplatin(60mg/$m^2$ iv. D1) etoposide(100mg/$m^2$ iv. D1-3), and 3 weeks later cyclophosphamide(1000mg/$m^2$ iv. D1), adriamycin( 40mg/$m^2$ iv. D1), and vincristine(1.4mg/$m^2$ iv. D1), were administered alternatively. CE group(n=22) was treated with carboplatin(325mg/$m^2$ iv. D1) and etoposide (100mg/$m^2$ iv. D1-3) ; repeated treatment was performed every 3 weeks. Result : Forty four patients were eligible for the study. The overall response rate was 61.4% (complete remission rate 0%, partial response rate 61.4%, stable disease rate 25%, progressive disease rate 13.6%), and median survival was 10.8 months. In VPP/CAV group, response rate was 54.5% (complete remission rate 0%, partial response rate 54.4%, stable disease rate 27.3%, progressive disease rate 18.2%), and, in carboplatin/etoposide group, the response rate was 68.2%(complete remission rate 0%, partial response rate 68.2%, stable disease rate 22.7%, progressive disease rate 9.1%). The median survival time was 9.5 months in the VPP/CAV group and 11 months in CE group. The toxicity of both group was moderate, and anemia was more frequent in the CE group. Conclusion : VPP/CAV regimen and CE regimen produced similar response rates and survival times in extensive stage small cell lung cancer patients. CE regimen may be effective as part of the initial therapy for extensive stage small cell lung cancer.

• Journal of Ginseng Research
• /
• v.26 no.2
• /
• pp.67-73
• /
• 2002

This study was done in order to evaluate the of effects on the blood lipid profiles, the body weight and body fat in 28 healthy female volunteers who had over 30% body fat by the long term intake of red ginseng product. Subjects were divided into four groups (placebo group n=7, red ginseng product group; n=7, exorcise group; n=7, exercise & red ginseng product group; n=7). Blood sampling and measuring of the body fat were taken by pre-treatment, 3 weeks, and after 12 weeks. Statistical techniques for data analysis were applied one-way ANOVA and repeated measures ANOVA. The 5% level of significance was used as the critical level for this study. In summary of results, total cholesterol, triglyceride and low density lipoproprotein cholesterol were reduced in three groups (red ginseng product group, p<0.001, exercise group, p<0.01 ; exercise & red ginseng product group, p<0.001) except placebo group. HDL-C was improved in three groups (red ginseng product group, p<0.05; exercise group, p<0.01; exercise & red ginseng product group, p<0.001) except placebo group. Body weight, percent body fat and body fat mass were reduced in three groups (red ginseng product group, p<0.01, exercise group, p<0.01 ; exercise & red ginseng product group, p<0.001) except placebo group. Finally, lean body mass was improved in three groups (red ginseng product group, p<0.05; exercise group, p<0.01; exercise & red ginseng product group, p<0.001) except placebo group.

• Journal of Gastric Cancer
• /
• v.3 no.3
• /
• pp.122-127
• /
• 2003

Purpose: The incidence rate and the mortality rate of gastric cancer have decreased in developed countries over the last several decades. On the other hand, they remain high in far eastern countries such as Korea, Japan, China and in many developing countries. The cure of patients with gastric carcinomas can be achieved mostly through complete surgical resection, but most gastric cancer patients are in advanced stages when diagnosed and have poor prognoses. therefore, the development of an effective systemic therapy is essential for far advanced gastric cancer patients. Until recently, the most commonly used combination chemotherapy was based on 5-flurouracil or cisplatin, but the results were not satisfactory, so recently etoposide, adriamycin and cisplatin (EAP-II) combination chemotherapy was introduced in patients with advanced gastric cancer. Early studies showed a high response rate and the ability to convert unresectable cases to resectable ones, but later studies couldn't duplicate the result. the purpose of this study was to evaluate the relative efficacy & toxicity of EAP-II chemotherapy and ELF chemotherapy which is based on 5-flurouracil. Materials and Methods: Between July 1992 and July 2002, sixty-five patients with inoperable advanced gastric cancer were enrolled for this study. Thirty-seven patient received EAP-II chemotherapy:etoposide (20 mg/$m^{2}$ IV for $1\∼5 days$), adriamycin (20 mg/$m^{2}$ IV for $1\∼5 days$) and cisplatin (20 mg/$m^{2}$ IV for $1\∼5 days$) and Twenty-eight patients receieved ELF chemotherapy : etoposide (100 mg/$m^{2}$ IV for $1\∼3 days$), leucovorin (20 mg/$m^{2}$ IV for $1\∼5 days$) and 5-FU (500 mg/$m^{2}$ IV for $1\∼5 days$). Each treatment schedule for each group was repeated every four weeks: EAP-II means 3.4 cycles per patient..ELF means 4.1 cycles per patient Results: Total respones rates were $5.4\%$ in the ELF group and $3.6\%$ in the EAP group (P-value>0.05). The median times to progression were 144 days in the ELF group and 92 days in the EAP-II group (P-value<0.05), and themedian overall survival times were 189 days in the ELF group and 139 days in the EAP-II group (P-value>0.05). The difference in the survival curves for the two regimens was not statistically significant. Non-hematologic toxicitis & hematologic toxicitis were more frequently observed for the EAP-II regimen. Anemia: $27.6\%$ in ELF vs $54\%$ in EAP-II; Leukopenia: $8.5\%$ in ELF vs $19\%$ in EAP-II; nausea & vomiting: $45.9\%$ in ELF vs $67.8\%$ in EAP-II. Conclusion: EAP-II regimen is not superior to ELF regimen in the tratment of inoperable advanced gastric cancer (J Korean Gastric Cancer Assoc 2003;3:122-127)

• Clinical and Experimental Pediatrics
• /
• v.45 no.5
• /
• pp.629-636
• /
• 2002

Purpose : Our study was aimed to investigate the characteristics of seizures as well as to determine whether the expression of neuronal nitric oxide synthase expression(nNOS) of hippocampus has an affect in the hyperthermic seizure in developing rat. Methods : Hyperthermic seizures were repeatedly induced twice a week for four weeks in 20-day old Spraque-Dowley rats. Fifty two rats were used as a hyperthermic group and 30 rats used as a normothermic control group. Hyperthermic seizures were induced in a water bath at $45^{\circ}C{\pm}1$ for 4 min. The characteristics of seizures were recorded. Using western blot, hippocampal nNOS expression was measured in normothermic control, hyperthermic non-seizure, and hyperthermic seizure groups, respectively. Results : Eighty seven percent of hyperthermia exposed rats showed generalized tonic-clonic seizure most frequently. The duration of seizure was ranged from 12 to 145 sec(mean 55 sec) and the latency to seizure ranged from 158 to 240 sec(mean 204 sec). The duration of seizure was prolonged but there was no significant difference in the seizure latency as the rat exposed more number of hyperthermia. Interestingly, the expression level of hippocampal nNOS in hyperthermic seizure and hyperthermic non-seizure groups was not different from each other, however, the expression in these groups was lower than that of the control group. Conclusion : Our results indicate that nNOS do not have an affect in this repeated hyperthermic seizures. Further studies are required to clarify a role of nNOS in hyperthermic seizure.

• Tuberculosis and Respiratory Diseases
• /
• v.58 no.4
• /
• pp.344-351
• /
• 2005

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine $25mg/m^2$ followed by an infusion of gemcitabine $1000mg/m^2$ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI 1-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness.

• Korean Journal of Poultry Science
• /
• v.35 no.4
• /
• pp.375-380
• /
• 2009

This study was conducted to investigate the effect of feeding induced molting on the visceral organs and blood component profile in laying hens and designed to test 400 flocks of 60 week old Leghorn laying hens for 34 weeks. A total of four molting treatment methods by including the molted with customary molting by fasting method (c), feeding single diet of corn (T1), feeding single diet of wheat bran (T2) and feeding single diet of alfalfa meal (T3) were tested, and each treatment was repeated for 5 times, and 20 laying hens were randomly assigned in an cage for each repeat. As the result of the experiment, ovary was $2.03{\sim}6%$ and oviduct was $2.51{\sim}3.47%$ in visceral organs for body weight at pre-molting term, but there was no significant difference. At post-molting, no significant difference was found, ovary was $0.25{\sim}0.41%$, uterus of control, T1, T2 and T3 was 1.12%, 0.82%, 0.48% and 0.90%, respectively. T2 was significantly lower than control, T3 (p<0.05) at the 50% of egg production. Ovary was $2.20{\sim}2.60%$ and oviduct was $2.98{\sim}3.45%$. In addition, ovary was $2.65{\sim}3.01%$, oviduct was $3.23{\sim}3.64%$ at the peak egg production, but there was no significant difference by non-feeding and feeding molting treatments. In blood component profile, cholesterol was $179.8{\sim}245.7\;mg/dL$ at pre-molting, but there was no significant difference and at post-molting, concentration of cholestrol in control, T1, T2 and T3 was 353.6, 229.1, 261.8 and 300.6 mg/dL, respectively. T1 was significantly lower than control and T3 (p<0.05). In addition, first laying day was $228.1{\sim}271.8\;mg/dL$, 50% of egg production was $236.5{\sim}284.8\;mg/dL$, there was no significant difference. Concentration of cholestrol in control, T1, T2 and T3 was 324.1, 591.6, 363.0 and 315.6 mg/dL, respectively, at the peak egg production period. T1 was significantly higher than other treatment (p<0.05).